FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients

The FDA approved Merck's Lipfendra, the first non-injectable pill to block PCSK9 and significantly reduce LDL cholesterol in high-risk patients. Clinical trials showed over 55% LDL reduction in six months, with minimal side effects, positioning it as an alternative to costly injectable PCSK9 inhibitors previously available from Amgen and others.